| Net income | 1.05B |
| Less: Income (loss) from discontinued operations | -1M |
| Income from continuing operations | 1.05B |
| Depreciation, decommissioning and amortization | |
| Regulatory impacts of net nuclear decommissioning trust earnings (reflected in accumulated depreciation) | |
| Other amortization | |
| Stock-based compensation | |
| Equity in income from unconsolidated affiliates - net | |
| Distributions from unconsolidated entities | |
| Deferred income taxes and investment tax credits | 127M |
| Proceeds from U.S. treasury grants | |
| Income from leveraged leases | |
| Receivables | -235M |
| Inventory | -43M |
| Margin and collateral deposits - net of collateral received | |
| Prepaid taxes | |
| Other current assets | |
| Rent payments in excess of levelized rent expense | |
| Accounts payable | 151M |
| Accrued taxes | |
| Other current liabilities | -68M |
| Derivative assets and liabilities - net | 15M |
| Regulatory assets and liabilities - net | |
| Other assets | |
| Other liabilities | |
| Operating cash flows from discontinued operations | |
| Net cash provided by operating activities | 2.5B |
| Long-term debt issued | 397M |
| Long-term debt issuance costs | |
| Long-term debt repaid | -83M |
| Bonds purchased | |
| Preference stock issued - net | 294M |
| Short-term debt financing - net | 60M |
| Settlements of stock-based compensation - net | |
| Dividends and distributions to noncontrolling interests | -98M |
| Dividends paid | -469M |
| Net cash provided by financing activities | -100M |
| Capital expenditures | -2.77B |
| Purchase of interest in acquired companies | |
| Proceeds from sale of nuclear decommissioning trust investments | 2.08B |
| Purchases of nuclear decommissioning trust investments and other | -1.92B |
| Proceeds from partnerships and unconsolidated subsidiaries, net of investment | |
| Investments in other assets | |
| Effect of consolidation and deconsolidation of variable interest entities | |
| Net cash used by investing activities | -2.48B |
| Net decrease in cash and cash equivalents | -77M |
| Cash and cash equivalents, beginning of period | 161M |
| Cash and cash equivalents, end of period | 84M |